Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

60%

3 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 4
3(60.0%)
N/A
2(40.0%)
5Total
Phase 4(3)
N/A(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT05426525Phase 4Active Not Recruiting

Use of Empagliflozin to Treat Prediabetes

Role: collaborator

NCT06605976Not ApplicableCompleted

Evaluating the Impact of Ambient AI on Documentation Efficiency and Clinician Burnout in Primary Care Settings

Role: lead

NCT05082441Phase 4Unknown

Liposomal Bupivacaine in Benign Soft Tissue Tumor Resection

Role: lead

NCT04473274Phase 4Completed

GlitazOne Treatment for Coronavirus HypoxiA, a Safety and Tolerability Open Label With Matching Cohort Pilot Study

Role: lead

NCT03284983Not ApplicableUnknown

Split Scar Study to Assess Cosmetic Outcome From Differing Suture Spacing

Role: collaborator

All 5 trials loaded